At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 2 enrolled
Drug / intervention
CS-7017drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extended Use of CS 7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Subjects With Cancer
In Brief
A Phase 1 clinical trial evaluating CS-7017 for Advanced Cancer. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This is a study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug. Participants who have not progressed while receiving CS-7017 will continue to benefit from longer administration of the agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedApr 2009
Primary CompletionMar 2011
Study CompletionSep 2011
TodayJul 2026
First PostedApr 15, 2009
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2011
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.2 years ago
Interventions
CS-7017drug
CS-7017 administered orally, twice daily continuously for 6 weeks